Regardless of surgical status, maintenance olaparib plus bevacizumab showed a significant progression-free survival( PFS ) benefit in newly diagnosed advanced ovarian cancer patients in clinical response after first-line platinum-based chemotherapy plus being administered. In patients with a BRCA1 / BRCA2 mutation or homologous recombination deficiency ( HRD, bRCAm, and / or genomic instability ), prespecified, exploratory analyses by molecular biomarker status showed significant benefit.